

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No. <u>09/451641</u>	Prepared by <u>LM</u>	Tracking Number <u>05874579</u>	
Examiner-GAU <u>Page - 16/15</u>	Date <u>1/23/04</u>	Week Date <u>12/15/03</u>	
	No. of queries <u>2</u>	IFW	

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

- a. Page Missing
- b. Text Continuity
- c. Holes through Data
- d. Other Missing Text
- e. Illegible Text
- f. Duplicate Text
- g. Brief Description
- h. Sequence Listing
- i. Appendix
- j. Amendments
- k. Other

CLAIMS

- a. Claim(s) Missing
- b. Improper Dependency
- c. Duplicate Numbers
- d. Incorrect Numbering
- e. Index Disagrees
- f. Punctuation
- g. Amendments
- h. Bracketing
- i. Missing Text
- j. Duplicate Text
- k. Other

MESSAGE

PTO-1449: Please either initial or line through citations. Copy provided for reference.

PTO-892: Please provide a clear copy. Data is unclear. Copy provided for reference.

Thank you
initials LM

RESPONSE

initials

(Rev. 8-88)

U.S. Department of Commerce
Patent and Trademark Office

C-3169/1/US

09/451,641

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)

TECH CENTER 1600 290

Desai et al., (1996). Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size. *Pharmaceutical Research*, Vol. 13, No. 12, pp. 1838-1845.Florence et al., (1995). Factors Affecting the Oral Uptake and Translocation of Polystyrene Nanoparticles: Histological and Analytical Evidence. *Journal of Drug Targeting*, Vol. 3, pp. 65-70.Gershank et al., (1998). Interaction of a Self-Emulsifying Liquid Drug Delivery System with the Everted Rat Intestinal Mucosa as a Function of Droplet Size and Surface Charge. *Pharmaceutical Research*, Vol. 15, No. 6, pp. 863-869.Kakoulides et al., (1998). Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity in vitro degradation and preliminary ex vivo bioadhesion studies. *Journal of Controlled Release*, 54 pp. 95-109.Kawamori et al., (1998). Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, against Colon Carcinogenesis. *Cancer Research*, 58, pp. 409-412.Kulvanich & Stewart, (1987). The effect of particle size and concentration on the adhesive characteristics of a model drug carrier interactive system. *J. Pharm. Pharmacol.*, 39, pp. 673-678.McClean et al., (1998). Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. *European Journal of Pharmaceutical Sciences*, (Website Version) Vol. 6, Issue 2, pp. 153-163.Rodriguez et al., (1998). Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. *Journal of Controlled Release*, 55, pp. 61-77.Rubinstein, (1995). Approaches and Opportunities in Colon-Specific Drug Delivery. *Critical Reviews in Therapeutic Drug Carrier Systems*, 12(283), pp. 101-149.Smith et al., (1998). Pharmacological analysis of cyclooxygenase-1 in inflammation. *Proc. Natl. Acad. Sci. USA*, Vol. 95, pp. 13313-13318.Trosch & Rubinstein, (1998). Migration of Adhesive and Nonadhesive Particles in the Rat intestine under Altered Mucus Secretion Conditions. *Journal of Pharmaceutical Sciences*, Vol. 87, No. 4, pp. 453-456.

Examiner

Date Considered

*Examiner

Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
(Use 8-600A sheets if necessary)

C-3169/1 09/451,641
Applicant:
Gao, D. et al.
Filing Date: November 30, 1999 Group No: 1615

RECEIVED

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
BH	9601455	Jul 29, 1996	Hungary	C07D	231:12		X
Examiner			Date Considered				
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

INFORMATION DISCLOSURE STATEMENT

(Use separate sheets if necessary)

C-3169/1/US

899/451,641

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

MAY 6 2 2002

U.S. PATENT DOCUMENTS

Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
S	AC 5,869,096	Feb 9, 1999	Barclay et al.	424	468	Dec 9, 1994
	AD 5,756,529	May 26, 1998	Isakson et al.	514	406	
	AE 5,633,272	May 27, 1997	Talley et al.	514	378	
	AF 5,474,784	Dec 12, 1995	Stevens et al.	424	456	
	AG 5,342,624	Aug 30, 1994	McNeill et al.	424	451	
	AH 4,866,848	Sep 12, 1989	Conte et al.	424	466	
C	AI 4,681,755	Jul 21, 1987	Colombo et al.	424	486	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
S	BC WO 97/44028	Nov 27, 1997	WIPO	A61K	31/365		X
S	BD WO 99/09988	Mar 4, 1999	WIPO	A61K	31/54		X

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

S	CD	Abdou (1989). Dissolution, Bioavailability and Bioequivalence. pp. 58-66, 457-458. Mack Publishing Co.
S	CE	American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5, 9-11, 26-33, 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129, 134-135, 138-140, 153-162, 166-169, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300, 304-308.
	CF	Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713.
	CG	Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available.
	CH	Bandeian (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutical Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker.
	CI	Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial Pharmacy, pp. 293-373. Lea & Febiger.
	CJ	DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co.
	CK	Göçgil (1991). Farmasötik Teknolojiye Başlangıç (In Turkish; believed to translate as "Introduction to Pharmaceutical Technology"), pp. 346-348. No English translation available.
	CL	Güven (1979). İlaç Endüstrisi Teknolojisi (In Turkish; believed to translate as "Drug Industry Technology"), pp. 67-81. No English translation available.
	CM	Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American College of Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998.
	CN	Igzu (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology"), Vol. 1, pp. 367-382. No English translation available.
	CO	Igzu (1983). Genel ve Endüstriyel Farmasötik Teknoloji - II (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology - II"), pp. 211-241. No English translation available.

Examiner

Date Considered

6/2/02

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT DOCUMENTS

	Document Number <small>(Patent Number and Kind Code)</small>	Date <small>(Month and Year)</small>	Name	Classification	
A	5,592,760	9 1996	Greenidge et al.	424	489
B	6,077,539	6 2000	Plachetka et al.	424	474
C	6,165,505	12 2000	Jain et al.	424	466
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

FOREIGN PATENT DOCUMENTS

	Document Number <small>(Country Code Number and Kind Code)</small>	Date <small>(Month and Year)</small>	Country	Name	Classification
X	N 0 863 134	9 1998	EP	Black	
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages				
U					
V					
W					
X					

* A copy of this reference is not being furnished with the Office action. (See MPEP § 102.05(a)). * Dates in YYYY format are publication dates. * Classifications may be in US or foreign.

Notice of References Cited

Susan Tran

1615

Page 1 of 1

U.S. PATENT DOCUMENTS

DOCUMENT NO	DATE	NAME	CLASS	SUBCLASS
A				
B				
C				
D				
E				
F				
G				
H				
I				
J				
K				
L				
M				

FOREIGN PATENT DOCUMENTS

DOCUMENT NO	DATE	COUNTRY	NAME	CLASS	SUBCLASS
X N 0 863 134	9/1998	EP	Black		
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

DOCUMENT (including Author, Title, Source, and Pertinent Pages)

DATE

CELECOXIB CAPSULES; U.S. Prescribing Information for CELEBREX by SEARLE Pfizer PHARMACIA

U

V

W

X

* A copy of this reference is not being furnished with this Office action.
See Manual of Patent Examining Procedure, Section 2012.03(a)